TABLE 2.

Clinicopathological Characteristics of Patients With Circulating Tumor Cells With a Mesenchymal-like Phenotype

Variable	CK+Vim+ CTCs (n = 26)	No CK+Vim+ CTCs (n = 24)	P**
Average age (yrs)	64.5 (27–85)	65.3 (40–86)	0.62
Male sex	19 (73%)	11 (46%)	0.11
Resectable disease	22 (85%)	22 (92%)	0.44
Tumor size (cm)	2.9 (0.1–8)	3.2 (0.2–6.3)	0.29
Average CA19-9 level (n = 39)	1189 (1–9032)	704 (0.6–7312)	0.88
CA19-9 level (n = 39)			0.61
High >36	15 (58%)	5 (38%)
Low <36	11 (42%)	8 (62%)
Tumor grade/differentiation			0.64
Well/moderate	12 (50%)	14 (64%)
Poor	12 (50%)	8 (36%)
Not specified	2	2
Perineural invasion	17 (77%)	20 (83%)	0.60
Perivascular invasion	11 (50%)	16 (67%)	0.83
Positive lymph nodes	17 (77%)	18 (78%)	0.25
Positive margin	5 (23%)	6 (27%)	0.41
Stage*			—
Stage I	4 (15%)	4 (17%)
Stage II	18 (70%)	20 (83%)
Stage III	0 (0%)	0 (0%)
Stage IV	4 (15%)	0 (0%)
Neoadjuvant chemotherapy	9 (35%)	7 (29%)	0.81
Adjuvant chemotherapy	19 (73%)	17 (71%)	0.97
SMAD4 (n = 46)			0.45
Intact	12 (50%)	12 (55%)
Lost	12 (50%)	10 (45%)
TP53 (n = 46)			0.36
Normal expression	8 (33%)	8 (33%)
Abnormal	16 (67%)	16 (67%)

Comparisons were performed for patients with and without cytokeratin-positive and vimentin-positive CTCs (CK+Vim+CTCs). Values are n (%) or mean (range).

^*P values for stage were not calculated given the small number of patients with stage I and IV disease, and that all patients with no mesenchymal-like CTCs had stage II disease.

^**P values from linear or logistic regression models for the association between the given patient characteristics and vimentin group while adjusting for whether the patient had cytokeratin-positive CTCs.